2.37% -0.0148

Dopo l'orario di chiusura: .60 -0.01 -1.64%

Icecure Medical Ltd (ICCM)

Icecure Medical Ltd Borsa (ICCM) Ultime notizie

Icecure Medical Ltd (ICCM)

Icecure Medical Ltd Borsa (ICCM) Ultime notizie

IceCure reports high success rate in breast cancer trial By Investing.com - Investing.com Australia

Ex-ad industry employees launch a new digital agency 'itch' - afaqs!

IceCure reports high success rate in breast cancer trial By Investing.com - Investing.com Canada

IceCure reports high success rate in breast cancer trial - Investing.com India

Why Is Interactive Strength Stock Surging Today? - Benzinga

IceCure reports high success rate in breast cancer trial - Investing.com

InCred's Aditya Sood Reveals Key Factors Behind Selecting Indraprastha Medical From Hospital Sector - Business Today

IceCure reports high success rate in breast cancer trial By Investing.com - Investing.com UK

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96 - StreetInsider.com

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate - PR Newswire

The time has not yet come to remove your chips from the table: Icecure Medical Ltd (ICCM) - SETE News

What will the future hold for Icecure Medical Ltd (NASDAQ:ICCM) stock? - US Post News

FDA AdComm to discuss IceCure's ProSense on Nov. 7 - MSN

Study: Liquid Nitrogen-Based Cryoablation Safe for Treating Treating Tumors of the Lung, Bone and Soft Tissues - Imaging Technology News

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues - StockTitan

H.C. Wainwright maintains Buy rating on IceCure Medical stock By Investing.com - Investing.com Canada

H.C. Wainwright maintains Buy rating on IceCure Medical stock - Investing.com India

Icecure Medical Ltd (ICCM) deserves closer scrutiny - US Post News

H.C. Wainwright maintains Buy rating on IceCure Medical stock - Investing.com

IceCure seeks FDA nod for breast cancer treatment - Investing.com

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 - PR Newswire

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 - StockTitan

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences - PR Newswire

Icecure Medical Ltd (ICCM) can make a big difference with a little luck - SETE News

Icecure Medical Ltd (ICCM) produces promising results - US Post News

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - The Malaysian Reserve

IceCure expands patent portfolio with USPTO allowance - Investing.com

IceCure Medical Strengthens Patent Portfolio - TipRanks

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - PR Newswire

IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com India

IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com Canada

IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com

IceCure Medical stock target cut, retains buy rating on Q2 results By Investing.com - Investing.com South Africa

IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com Australia

IceCure Medical stock target cut, retains buy rating on Q2 results - Investing.com UK

IceCure Medical Ltd (NASDAQ:ICCM) Q2 2024 Earnings Call Transcript - Insider Monkey

Earnings call: IceCure Medical reports growth and upcoming FDA panel - Investing.com India

Earnings call: IceCure Medical reports growth and upcoming FDA panel By Investing.com - Investing.com Australia

Earnings call: IceCure Medical reports growth and upcoming FDA panel By Investing.com - Investing.com Canada

Earnings call: IceCure Medical reports growth and upcoming FDA panel - Investing.com

Earnings call: IceCure Medical reports growth and upcoming FDA panel By Investing.com - Investing.com UK

IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates - MSN

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets - The Malaysian Reserve

IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets - PR Newswire

ICCM (Icecure Medical) Days Inventory : 422.18 (As of Mar. 2024) - GuruFocus.com

IceCure Medical (ICCM) Set to Announce Earnings on Tuesday - Defense World

IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024 - Longview News-Journal

IceCure Medical Takes Next Major Initiative as it Prepares to Ac - GuruFocus.com

Icecure's Prosense destroys 100% of breast cancer tumors - BioWorld Online

Taking the lead: Icecure Medical Ltd (ICCM) - SETE News

ICCM (Icecure Medical) Financial Strength : 5 (As of Mar. 2024) - GuruFocus.com

Icecure Medical Ltd [ICCM] moved down -3.91: Why It’s Important - The DBT News

Closing Bell Recap: Icecure Medical Ltd (ICCM) Ends at 0.59, Reflecting a -3.91 Downturn - The Dwinnex

Icecure Medical Ltd (ICCM) Stock: A Comprehensive 52-Week Review - The InvestChronicle

ICCMIceCure Medical Ltd Latest Stock News & Market Updates - StockTitan

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery - PR Newswire

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery - StreetInsider.com

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024 - The Malaysian Reserve

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024 - Quantisnow

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024 - PR Newswire

Market Update: Icecure Medical Ltd (ICCM) Sees Negative Movement, Closing at 0.60 - The Dwinnex

Large study supports cryoablation for inoperable breast cancer - Investing.com

Large study supports cryoablation for inoperable breast cancer By Investing.com - Investing.com Canada

Simile a ICCM